MUNITA SEPULVEDA, JOSE MANUEL
Preferred name
MUNITA SEPULVEDA, JOSE MANUEL
Main Affiliation
Email
josemunita@udd.cl
ORCID
0000-0002-7870-1056
Scopus Author ID
24825037700
139 results
Now showing 1 - 10 of 139
- Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - Geographic divergence of methicillin-resistant Staphylococcus aureus ST5-SCCmecI in the aftermath of a major earthquake and tsunami: impact of a plasmid harboring heavy metal resistance genes(United States National Library of Medicine, 2025); ; ; ;ROBERTO ANDRES RIQUELME NEIRA - Some of the metrics are blocked by yourconsent settings
Item type:Publication, <i>In Vivo</i> Resistance to Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Arising by AmpC- and Non-AmpC-Mediated Pathways(2018) ;Erik Skoglund ;Henrietta Abodakpi ;Rafael Rios ;Lorena DiazElsa De La Cadena<jats:p>Two pairs of ceftolozane/tazobactam susceptible/resistant <jats:italic>P. aeruginosa</jats:italic> were isolated from 2 patients after exposure to <jats:italic>β</jats:italic>-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and <jats:italic>β</jats:italic>-lactam-resistant mechanisms were assessed by phenotypic assays. Whole genome sequencing identified mutations in AmpC including the mutation (V213A) and a deletion of 7 amino acids (P210–G216) in the Ω-loop. Phenotypic assays showed that ceftolozane/tazobactam resistance in the strain with AmpC<jats:sub>V213A</jats:sub> variant was associated with increased <jats:italic>β</jats:italic>-lactamase hydrolysis activity. On the other hand, the deletion of 7 amino acids in the Ω-loop of AmpC did not display enhanced <jats:italic>β</jats:italic>-lactamase activity. Resistance to ceftolozane/tazobactam in <jats:italic>P. aeruginosa</jats:italic> is associated with changes in AmpC; however, the apparent loss of <jats:italic>β</jats:italic>-lactamase activity in AmpC∆7 suggests that non-AmpC mechanisms could play an important role in resistance to <jats:italic>β</jats:italic>-lactam/<jats:italic>β</jats:italic>-lactamase inhibitor combinations.</jats:p>4 - Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries(National Library of Medicine, 2022); JOSE RODRIGO WALDEMAR MARTINEZ SOLIS9 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cost-effectiveness of screening, decolonisation and isolation strategies for carbapenem-resistant Enterobacterales and methicillin-resistant Staphylococcus aureus infections in hospitals: a sex-stratified mathematical modelling study(Elsevier BV, 2025-03) ;Kasim Allel ;Patricia Garcia ;Anne Peters; Eduardo A. Undurraga2 - Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - Dynamics of the MRSA Population in a Chilean Hospital: a Phylogenomic Analysis (2000-2016)(2023) ;MARTINEZ SOLIS, JOSE RODRIGO WALDEMAR ;SPENCER SANDINO, MARÍA DE LOS ÁNGELES; ;DIAZ ORTIZ, SANDRA5 - Some of the metrics are blocked by yourconsent settings
Item type:Product, 11 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DO INTERNATIONAL MIGRANTS FACE HIGHER BACTERIAL DRUG RESISTANCE COMPARED TO NATIVES? A SYSTEMATIC REVIEW(2019); ; ;Anne Peters ;Acuna, M. PNorman Uphoff7 - Some of the metrics are blocked by yourconsent settings
Item type:Product, - Some of the metrics are blocked by yourconsent settings
Item type:Product, 15 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)(2021) ;German A Contreras; ;Shelby Simar ;Courtney LuterbachAn Q Dinh<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Vancomycin-resistant enterococci (VRE) are major therapeutic challenges. Prospective contemporary data characterizing the clinical and molecular epidemiology of VRE bloodstream infections (BSIs) are lacking.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The Vancomycin-Resistant Enterococcal BSI Outcomes Study (VENOUS I) is a prospective observational cohort of adult patients with enterococcal BSI in 11 US hospitals. We included patients with Enterococcus faecalis or Enterococcus faecium BSI with ≥1 follow-up blood culture(s) within 7 days and availability of isolate(s) for further characterization. The primary study outcome was in-hospital mortality. Secondary outcomes were mortality at days 4, 7, 10, 12, and 15 after index blood culture. A desirability of outcome ranking was constructed to assess the association of vancomycin resistance with outcomes. All index isolates were subjected to whole genome sequencing.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Forty-two of 232 (18%) patients died in hospital and 39 (17%) exhibited microbiological failure (lack of clearance in the first 4 days). Neutropenia (hazard ratio [HR], 3.13), microbiological failure (HR, 2.4), VRE BSI (HR, 2.13), use of urinary catheter (HR, 1.85), and Pitt BSI score ≥2 (HR, 1.83) were significant predictors of in-hospital mortality. Microbiological failure was the strongest predictor of in-hospital mortality in patients with E faecium bacteremia (HR, 5.03). The impact of vancomycin resistance on mortality in our cohort changed throughout the course of hospitalization. Enterococcus faecalis sequence type 6 was a predominant multidrug-resistant lineage, whereas a heterogeneous genomic population of E faecium was identified.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Failure of early eradication of VRE from the bloodstream is a major factor associated with poor outcomes.</jats:p> </jats:sec>5Scopus© Citations 42